About Florida Cancer Specialists & Research Institute, LLC: (Homepage)
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
Texas Colon & Rectal Specialists Join Texas Oncology and The US Oncology Network
April 2nd 2021Surgical oncology expertise has been expanded to local communities in North Texas after physicians from Texas Colon & Rectal Specialists, a large colorectal cancer practice in North Texas, have joined Texas Oncology, increasing The US Oncology Network’s reach.
Read More
COVID-19 Decreased, Delayed Cancer Identification and Treatment Delivery, Study Shows
November 7th 2020Significant short-term disruptions in care delivery were observed during the coronavirus disease 2019 pandemic, which may have long-term consequences in morbidity and survival implications for patients who were unable to receive cancer screening, treatment, and surgery throughout this time.
Read More
FCS Names Shekeab Jauhari as Principal Investigator for their New Drug Development Unit
December 26th 2019Shekeab Jauhari, MD, a medical oncologist/hematologist, has been named principal investigator at the Florida Cancer Specialists & Research Institute, and he will lead phase I clinical trials at the FCS Drug Development Unit in Lake Mary, Florida, at the Sarah Cannon Research Institute, which is the newest unit in the FCS that is set to open in January 2020.
Read More
Discussing the Benefits of Trilaciclib Plus Topotecan for Treatment of Extensive-stage SCLC
August 27th 2019Lowell L. Hart, MD, FACP, scientific director of clinical research, Florida Cancer Specialists & Research Institute, and associate professor of medicine, Wake Forest University School of Medicine, discusses the effect of CDK4/6 inhibitor, trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Hart presented the phase II results from the blinded, multicenter study during the 2019 ASCO Annual Meeting.
Watch
FCS and Cigna Create New Initiative Focused on Better Patient Experience
August 23rd 2019Florida Cancer Specialists & Research Institute has announced an oncology-focused initiative with Cigna as a part of the Cigna Collaborative Care. The Cigna Oncology Focus program's main goal is to provide quality care and contain costs for people with cancer. It also uses incentives to encourage healthcare professionals to improve affordability, as well as patients health and overall experience.
Read More
Improving Community Oncology Practices Through the American Oncology Network
June 20th 2019The American Oncology Network is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.
Watch
Costs at Hospital-Based Oncology Practices Continue to Outpace Those of Community Cancer Clinics
June 13th 2019In the current oncology climate, the search for affordable access to cancer care is a growing concern because of the steep price of treatment advancements, inpatient, outpatient, and ED costs, and financial bankruptcy or mergers that limit the number of community cancer clinics. During the 2019 Community Oncology Alliance annual conference in Orlando, Florida, Lucio N. Gordan, MD, of Florida Cancer Specialists & Research Institute addressed the complex challenges faced by community oncology clinics.
Read More
Addressing the State of Community Oncology in Florida and the Role of FLASCO
June 11th 2019Eric Harris, DO, hematologist/oncologist, Florida Cancer Specialists & Research Institute, gives Targeted Oncology an insiders perspective on the current state of community oncology in Florida and some ways the Florida Society of Clinical Oncology (FLASCO) aids in improving patient care by helping physicians.
Watch
Despite Initial Challenges, Oncology Practices See Benefit Moving to Oncology Care Model
May 14th 2019Oncology practices that adopt the OCM developed by the CMS face a tough road. The transformation requires changes in infrastructure encompassing administrative and care management service lines, as well as a change in philosophical outlook for clinicians and physician leadership; translational services for clinical interpretation; and internal reporting that is both costly and complex.
Read More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Taking on the Hospital/Community Practice Cost Differential
January 24th 2018Just as CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, results from a new study show that cancer treatment costs remain significantly lower at community oncology clinics compared with hospitals.
Read More
FDA Grants Approval to Co-Packaging of Ribociclib With Letrozole for Metastatic Breast Cancer
May 10th 2017The FDA has given its approval to co-packaging of the oral medications ribociclib (Kisqali) and letrozole (Femara) for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.
Read More
Ribociclib Results Promising for Elderly Patients With HR+/HER2- Breast Cancer
March 10th 2017The addition of the CDK4/6 inhibitor ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Read More